Subscribe to access the full database, or Start Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory	⤷ Start Trial	Hg^L`Fh{@HrIQPqQJKmTuUMHet@	⤷ Start Trial
Sigma-Aldrich	⤷ Start Trial	C8856_SIAL	⤷ Start Trial
Calbiochem	⤷ Start Trial	211875	⤷ Start Trial
NovoSeek	⤷ Start Trial	44093	⤷ Start Trial
Sigma-Aldrich	⤷ Start Trial	C4042_SIGMA	⤷ Start Trial
Vitas-M Laboratory	⤷ Start Trial	STK802012	⤷ Start Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: February 20, 2026

Multiple manufacturers supply bulk Captopril, a prominent ACE inhibitor used to treat hypertension and heart failure. The API sourcing landscape includes both global pharmaceutical ingredient producers and specialized chemical suppliers.

Who Are Major API Suppliers for Captopril?

Company	Location	Certification	Production Capacity	Market Focus	Notes
Hangzhou Huadong Pharmaceutical Co.	China	cGMP, ISO 9001	High volume	Global, mainly Asia Pacific	One of the leading producers with extensive API output
Zhejiang Huahai Pharmaceutical Co.	China	cGMP, ISO 9001	Large scale	North America, Europe, Asia	Supplies multiple APIs including Captopril
Zhejiang REKEEN Pharmaceutical Co.	China	cGMP	Moderate to high	Asia, some export markets	Focus on cardiovascular APIs
AOP Orphan Pharmaceuticals	Austria	cGMP	Niche manufacturer	Specialty market	Focuses on high-quality APIs with strict standards
Solara Active Pharma Sciences	India	cGMP	Growing capacity	Global markets, regulated segments	Produces both intermediates and APIs

Key API Production Attributes

Manufacturing Standards: All suppliers listed adhere to current Good Manufacturing Practices (cGMP). This compliance ensures high-quality API production suitable for regulated markets.
Raw Material Sourcing: Chinese manufacturers typically source raw materials domestically or via reliable international suppliers, ensuring supply chain stability.
Quality Certifications: ISO 9001 is common among suppliers, with cGMP certification crucial for APIs intended for pharmaceutical use.
Production Scale: Capacity varies from moderate to large scale; China-based suppliers dominate the market, offering large-volume production capable of supporting global demand.

API Market Trends and Sourcing Dynamics

Supply Concentration: Over 70% of Captopril API comes from China, due to lower production costs and established manufacturing infrastructure.
Regulatory Barriers: Suppliers serving North American and European markets often have additional certifications, inspections, and documentation to meet strict regulatory standards.
Price Trends: API costs have decreased over the past decade, driven by increased Chinese capacity and competition among suppliers.
Supply Chain Risks: Political tensions, trade restrictions, and quality concerns impact sourcing decisions, prompting some companies to diversify suppliers or source from multiple regions.

Quality and Regulatory Considerations

GMP Certification: Essential for APIs intended for prescription drugs within regulated markets.
Documentation: Certificates of Analysis (CoA), Certificates of Compliance (CoC), and Batch Records are standard, ensuring traceability.
Stability Data: Suppliers provide stability information confirming API shelf life under specified storage conditions, critical for formulation and storage planning.
Pre-approval Inspections: Regulatory agencies such as the FDA, EMA, and PMDA may conduct inspections before approving facilities for API manufacturing.

Sourcing Strategies

Direct Procurement: Engage directly with manufacturers possessing cGMP certifications with verified quality records.
Trade Brokers and Distributors: Use authorized distributors for bulk purchasing, ensuring quality compliance and logistical support.
Dual sourcing: To mitigate risks, companies often establish supply agreements with multiple suppliers, mainly from China and India.

Regulatory & Compliance Outlook

New regulations aim to improve API quality standards globally. The US FDA’s Drug Quality and Security Act (DQSA) emphasizes supply chain security.
Importers must verify supplier certifications, conduct audits, and retain documentation to meet regulatory requirements.

Summary

Major sources of bulk Captopril API are predominantly Chinese manufacturers, with a handful of European and Indian firms offering compliant, high-quality production. Suppliers universally adhere to cGMP standards, with quality certifications crucial for market acceptance. The sourcing landscape is influenced by regional regulations, capacity, and supply chain stability.

Key Takeaways

China dominates the Captopril API supply chain, contributing over 70% of global production.
Suppliers must maintain cGMP and ISO 9001 certifications for markets requiring high regulatory compliance.
Market trends favor diversification due to geopolitical and supply chain risks.
Price competition persists, driven by increased Chinese manufacturing capacity.
Partnerships with certified distributors can facilitate compliance and supply stability.

FAQs

What are the leading API manufacturers for Captopril?
Hangzhou Huadong Pharmaceutical and Zhejiang Huahai Pharmaceutical lead in production capacity and market reach.
Are Chinese API manufacturers compliant with international standards?
Yes. Most Chinese suppliers meet cGMP and ISO 9001 standards, suitable for global markets.
How does regulatory compliance impact sourcing choices?
Suppliers with strict certifications and comprehensive documentation are preferred for regulated markets, reducing approval risks.
Is dual sourcing recommended for Captopril API?
Yes. To mitigate supply disruptions and geopolitical risks, companies often source from multiple manufacturers.
What are current trends influencing API pricing?
Competition among Chinese suppliers and increased manufacturing capacity have driven down prices over recent years.

References

[1] U.S. Food and Drug Administration. (2022). Current Good Manufacturing Practice (CGMP) Regulations. https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practices-cgmp

[2] European Medicines Agency. (2021). Guidelines on the quality of unlicensed medicines. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-unlicensed-medicines_en.pdf

[3] PricewaterhouseCoopers. (2020). API Market Overview and Trends. https://www.pwc.com/gx/en/industries/pharmaceuticals-life-sciences/publications/api-market.html

[4] National Pharmaceutical Regulatory Agency. (2022). API Manufacturing Standards and Certification. https://npra.gov.my

[5] Market Research Future. (2021). API Market Analysis and Forecast. https://www.marketresearchfuture.com

Bulk Pharmaceutical API Sources for CAPTOPRIL